🔬 What the Data Shows: Long-Term Methylphenidate Use and Growth
In children who took methylphenidate for 2+ years, small reductions of approximately 1.4cm in height and 2.0kg in weight were observed. However, many studies also report recovery trends after discontinuation or during puberty.
We need to look at the data behind the "growth suppression" concern that worries parents most. A 1.4cm difference over 2 years is statistically significant, but its clinical significance remains debated. This does not mean "medication stops growth," but rather "a slight deceleration is observed and monitoring is needed." As supporting evidence, a Lancet Psychiatry 2025 cardiovascular network meta-analysis (102 RCTs) confirmed that mild increases in blood pressure and heart rate were observed, but no serious cardiovascular events were reported.
- Debate over the clinical significance of the effect size continues.
- Very long-term (10+ year) follow-up data are extremely limited.
- Cardiovascular effects show mild blood pressure/heart rate increases, but no serious cardiovascular events have been reported.
- Individual variation is large, so the same impact cannot be expected for every child.
- ① At regular checkups, ask your doctor to check height, weight, and blood pressure together.
- ② Track growth trends — plotting on growth curves every 6 months to 1 year helps you see changes objectively.
- ③ If you have growth concerns, ask your specialist directly: "Is the medication affecting my child's growth?"
- ④ Medication changes/discontinuation must be decided with your specialist — don't stop on your own due to growth worries alone.
🔬 What the Data Shows: Cochrane's Evidence Certainty Rating
Cochrane systematically reviewed studies of methylphenidate in children/adolescents with ADHD and rated the certainty of evidence as "very low." When this appeared in news headlines, it amplified parental anxiety.
This is the most commonly misunderstood point. Cochrane's "very low" rating does not mean "the drug doesn't work." The included RCTs had high risk of bias (broken blinding, high attrition rates), inadequate side effect reporting, and high between-study heterogeneity.
In contrast, Cortese et al.'s network meta-analysis (Lancet Psychiatry 2018, 133 RCTs) confirmed the drug's efficacy while applying different methodological criteria. In other words, evaluating the same data with different criteria can yield different conclusions. This is part of scientific debate, not a matter of "one side being wrong."
- Differences between Cochrane and NMA interpretations stem from methodological (bias assessment criteria) differences.
- Under-reporting of side effects in included studies is noted.
- News outlets sometimes confuse "evidence certainty" with "effect size" in reporting.
- Using this review as justification to discontinue medication on your own is inappropriate.
- ① Don't just read the headline — check "who evaluated it and by what criteria."
- ② "Evidence is weak" ≠ "No effect" — remember this distinction.
- ③ Ask your specialist — "What do you think about the recent Cochrane review?"
- ④ Even after reading alarming articles, always discuss medication changes/discontinuation with your physician first.
- "My child has been on medication for a long time — how can I check if it's affecting growth?"
- "I'm worried about cardiovascular side effects — are there regular checks I should request?"
- "I read an article saying 'ADHD drug evidence is weak' — is it okay to continue medication?"
- "Why do the Cochrane review and other studies reach different conclusions?"
- "How should I start combining non-medication approaches (behavioral therapy, parent training) with medication?"
| Item | AAP (American Academy of Pediatrics) | NICE (UK) |
|---|---|---|
| First-line (age 6+) | Medication + behavioral therapy combined | Methylphenidate |
| Ages 4–5 | Behavioral therapy first; medication if insufficient | Parent training first; medication for moderate-severe |
| Growth monitoring | Regular height/weight tracking recommended | Height, weight, heart rate, BP every 6 months |
| Cardiovascular screening | History/family history check; routine ECG not required | Pre-prescription HR/BP, family history check |
| Drug holiday | Review when needed | Re-evaluation at least once per year recommended |
※ AAP: Wolraich et al. (2019), NICE NG87 (2018, 2024 updated). Guidelines may be applied differently depending on region and healthcare system.
- 📊 Evidence Level: Long-term safety (Grade B, Systematic Review + Meta-Analysis), Evidence certainty (Grade B, Cochrane Systematic Review). Both are high-level reviews, but bias risk in included studies and limited long-term data are shared limitations.
- 💊 Strict Medication Caution: Nothing in this report directs you to prescribe, change, or discontinue medication. All medication decisions must be discussed in person with your healthcare provider.
- 🎯 Individual Variation: All results are statistical averages. Please work with your physician and specialist to design "a personalized management plan for your child."